Empowering Members Through Biohealth Advocacy
BioForward’s advocacy efforts are designed to directly benefit biohealth companies in Wisconsin. By educating policymakers and actively engaging in legislative activities, we ensure policies that support industry growth and innovation are prioritized. By being part of BioForward, members gain a powerful ally dedicated to their success and the growth of the entire biohealth ecosystem.
Latest Legislative Activities
We actively engage in legislative activities to influence policies that support the growth and success of Wisconsin’s biohealth industry.
Supplemental Breast Cancer Screening (2025 Wisconsin Act 103)
Signed March 19, 2026. Requires insurance coverage for medically necessary supplemental screenings and diagnostic breast examinations for individuals with dense breast tissue or increased risk.
R&D Tax Credit Increase in Carryover Period (2025 Wisconsin Act 220)
Signed April 8, 2026. Allows unused research tax credits to be carried forward for up to 50 years, providing significantly more flexibility for companies investing in long-term innovation.
R&D Sales & Use Tax Exemption (CRO Services)
Signed April 3, 2026. Extends Wisconsin’s existing sales and use tax exemption for purchases of equipment used in qualified research to contract research organizations, reducing the cost of research infrastructure and strengthening the state’s competitive position for outsourced and collaborative R&D.
SBIR/STTR Reauthorization
SBIR/STTR legislation has passed both the Houseand Senate providing funding through 2031.Waiting for final approval.
Most Favored Nation Pricing
HR 7837 adopting foreign price controls would jeopardize patient access to innovative medicines. The absence of price controls in the U.S. leads to more and newer medicines made available sooner to Americans, with better health outcomes for those with serious diseases.
Biopharmaceutical innovation depends on long-term, high-risk investments. But MFN policies that tie U.S. prices to those set by foreign governments fundamentally reshape investment decisions and discourage the development of new medicines. Drug development often takes more than a decade and billions of dollars before patients see a new treatment. MFN imposes price ceilings by importing foreign government price controls, which can reduce the predictability of future revenues and results in fewer companies being able to attract the capital required to fund early-stage research. This can narrow the pipeline of new medicines before they ever reach patients.
National Biotechnology Initiative Act (H.R. 2756)
A whole of government approach to advancingbiotechnology for U.S. national security, economic productivity, andcompetitiveness. The legislation would establish a National BiotechnologyCoordination Office within the Executive Office of the President to lead andcoordinate federal biotechnology efforts.
Advocacy Insights
Stay updated with the latest advocacy news and insights. We share important developments and policy changes affecting the biohealth industry, ensuring our members are well-informed.
Discover the remarkable growth and innovation of Wisconsin’s biohealth industry.
The information policymakers need to support a thriving industry driving Wisconsin’s economic recovery.
The information policymakers need to support a thriving industry driving Wisconsin’s economic recovery.
This legislation ensures that copay assistance counts toward patients' out-of-pocket costs, preventing insurers from excluding these payments from deductibles.
Government Affairs Committee
Our Government Affairs Committee represents member interests, ensuring their voices are heard and their needs are addressed at every level of government.
.png)
.png)
Find Your Legislators & Legislative Committees
Stay informed and make your voice heard. BioForward periodically issues legislative alerts, encouraging members to contact their senators or representatives on critical biohealth industry issues. Locate your legislators using our interactive map and get involved today.
